Table 4 Multivariable logistic regression analysis for publication status
Characteristics | Crude OR | 95% CI | Adjusted OR | 95% CI |
|---|---|---|---|---|
Drug | ||||
Vitamin D | 1.00 | Ref | ||
Corticosteroid | 0.71 | 0.36–1.42 | ||
Hydroxychloroquine | 0.78 | 0.42–1.46 | ||
Parallel study design | 0.67 | 0.25–1.77 | ||
Phase 3 or 4 | 1.47 | 0.82–2.63 | 1.28 | 0.92–1.78 |
Multinational | 1.88 | 0.75–4.68 | 0.96 | 0.32–2.86 |
> 2 randomised groups | 0.71 | 0.41–1.22 | 0.56 | 0.28–1.09 |
Placebo controlled | 1.54 | 0.95–2.49 | 1.34 | 0.75–2.39 |
Primary sponsor | ||||
Academic | 1.00 | Ref | ||
Research institute | 0.56 | 0.25–1.26 | 0.38 | 0.15–0.95 |
Government | 0.67 | 0.22–2.01 | 0.26 | 0.07 to 0.89 |
Medical centre | 0.46 | 0.26–0.82 | 0.28 | 0.14–0.56 |
Pharmaceutical | 0.87 | 0.28–2.71 | 0.96 | 0.29–3.21 |
Other | 1.4 | 0.69–2.95 | 0.85 | 0.36–2.04 |
Email address on ICTRP | 0.49 | 0.31–0.78 | 0.32 | 0.18–0.58 |
Target sample size | ||||
≤ 100 | 1.00 | Ref | ||
> 100 ≤ 300 | 1.5 | 0.88–2.65 | 2.1 | 1.08–4.1 |
> 300 | 1.85 | 1.05–3.25 | 2.75 | 1.35–5.62 |
Blinding | 1.31 | 0.8 – 2.14 |